Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Potassium Canrenoate in Brain-dead Organ Donors
NCT04714710Phase 2Active, not recruiting
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of potassium canrenoate in ischemia-reperfusion injury (IRI). Started Aug 2021; status: active, not recruiting.
02
Drugs
potassium canrenoate
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT04714710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714710.